Plus Therapeutics (PSTV) Net Income towards Common Stockholders (2011 - 2026)
Plus Therapeutics (PSTV) reported Net Income towards Common Stockholders of -$6.9 million for Q1 2026, down 70.12% year-over-year from -$23.2 million in Q1 2025, and down 21.58% quarter-over-quarter from -$5.7 million in Q4 2025.
Plus Therapeutics (PSTV) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$6.9 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$6.9 million, down 70.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.6 million (down 20.55% YoY), and the FY2025 annual result was -$15.7 million, down 7.73% from the prior year.
- Net Income towards Common Stockholders slipped to -$6.9 million in Q1 2026 per PSTV's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$1.5 million in Q2 2023 and troughed at -$6.9 million in Q1 2026.
- A 5-year average of -$4.2 million and a median of -$4.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 71.94% in 2023, then tumbled 146.76% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$5.6 million in 2022, then jumped by 32.09% to -$3.8 million in 2023, then fell by 2.44% to -$3.9 million in 2024, then tumbled by 46.37% to -$5.7 million in 2025, then fell by 21.58% to -$6.9 million in 2026.
- Business Quant data shows PSTV's Net Income towards Common Stockholders at -$6.9 million in Q1 2026, -$5.7 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Plus Therapeutics | 35.99 Mn | 20.87 Mn | - | -6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.95 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -4.42 Mn |
| Jun 30, 2025 | -1.51 Mn |
| Mar 31, 2025 | -4.08 Mn |
| Dec 31, 2024 | -3.90 Mn |
| Sep 30, 2024 | -3.78 Mn |
| Jun 30, 2024 | -3.66 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | -3.22 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -4.81 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -5.25 Mn |
| Jun 30, 2022 | -5.28 Mn |
| Mar 31, 2022 | -4.12 Mn |
| Dec 31, 2021 | -4.13 Mn |
| Sep 30, 2021 | -3.69 Mn |
| Jun 30, 2021 | -2.77 Mn |